You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Pharmacology and psychology of Chemsex and DDIs with ART

Over recent years there has been an increase in the use of chemsex and chems amongst MSM, which is associated with an increased risk of STIs and HIV transmission and can also compromise adherence to ART1-4. ViiV Healthcare held a webinar to discuss the pharmacology and psychology of chemsex and DDIs with ART. This webinar is presented by:

Chapter 1: Chemsex: the risks, pharmacology and psychology

Presented by Annemiek De Ruiter, Senior Global Medical Director at ViiV Healthcare

Chapter 2: What are the Chems and a brief overview of their pharmacology and pharmacokinetics

Presented by Chinyere Okoli, Medical Advisor at ViiV Healthcare

Chapter 3: Who are the patients at risk? What are the psychological considerations?

Presented by Robert Palmer, Psychosexual Counselor

Chapter 4: Summary and Q&A

Presented by Annemiek De Ruiter, Senior Global Medical Director at ViiV Healthcare

TRIUMEQ is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40kg.

Before initiating treatment with abacavir-containing products, HLA-B*5701 status must always be documented. Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to the risk of hypersensitivity reaction.

TIVICAY is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adults, adolescents and children aged 6 years and over, weighing at least 15kg.

CELSENTRI, in combination with other antiretroviral medicinal products, is indicated for treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable



Product information

Prescribing information



Prescribing information


  1. Sewell Int J Drug Policy 2017
  2. Ottaway Int J STD & AIDS 2017
  3. Ottaway et al, Sex trans Infect 2017: Increasing rates of reported chemsex/sexualised recreational drug use in men who have sex with men attending for postexposure prophylaxis for sexual exposure.
  4. ASTRA study

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Tivicay & Triumeq are registered trademark of the GlaxoSmithKline Group of Companies.